FBIO vs. ACHV, LXRX, RGLS, DOMH, AGEN, CRIS, BOLT, SABS, MTEM, and AMGN
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Achieve Life Sciences (ACHV), Lexicon Pharmaceuticals (LXRX), Regulus Therapeutics (RGLS), Dominari (DOMH), Agenus (AGEN), Curis (CRIS), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), and Amgen (AMGN). These companies are all part of the "biotechnology" industry.
Fortress Biotech vs.
Achieve Life Sciences (NASDAQ:ACHV) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
Achieve Life Sciences has a net margin of 0.00% compared to Fortress Biotech's net margin of -84.53%. Fortress Biotech's return on equity of 0.00% beat Achieve Life Sciences' return on equity.
Achieve Life Sciences received 6 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 70.46% of users gave Achieve Life Sciences an outperform vote while only 63.69% of users gave Fortress Biotech an outperform vote.
Achieve Life Sciences has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.
In the previous week, Achieve Life Sciences had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for Achieve Life Sciences and 5 mentions for Fortress Biotech. Achieve Life Sciences' average media sentiment score of 1.35 beat Fortress Biotech's score of 0.38 indicating that Achieve Life Sciences is being referred to more favorably in the media.
Achieve Life Sciences presently has a consensus price target of $15.75, indicating a potential upside of 450.70%. Fortress Biotech has a consensus price target of $21.00, indicating a potential upside of 1,100.00%. Given Fortress Biotech's higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Achieve Life Sciences.
Achieve Life Sciences has higher earnings, but lower revenue than Fortress Biotech. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by insiders. Comparatively, 33.4% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Achieve Life Sciences beats Fortress Biotech on 9 of the 17 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:FBIO) was last updated on 3/25/2025 by MarketBeat.com Staff
